Silvercrest Asset Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.85M | Sell |
12,125
-900
| -7% | -$138K | 0.01% | 536 |
|
|
2025
Q4 | $1.8M | Buy |
13,025
+1,486
| +13% | +$195K | 0.01% | 545 |
|
|
2025
Q3 | $1.48M | Buy |
11,539
+105
| +0.9% | +$12.8K | 0.01% | 574 |
|
|
2025
Q2 | $1.38M | Sell |
11,434
-237
| -2% | -$26.7K | 0.01% | 596 |
|
|
2025
Q1 | $1.3M | Buy |
11,671
+1,527
| +15% | +$163K | 0.01% | 591 |
|
|
2024
Q4 | $987K | Buy |
10,144
+558
| +6% | +$59.5K | 0.01% | 616 |
|
|
2024
Q3 | $1.1M | Sell |
9,586
-658
| -6% | -$74.7K | 0.01% | 561 |
|
|
2024
Q2 | $1.09M | Sell |
10,244
-750
| -7% | -$75.3K | 0.01% | 616 |
|
|
2024
Q1 | $1.06M | Buy |
10,994
+500
| +5% | +$51.3K | 0.01% | 601 |
|
|
2023
Q4 | $1.06M | Sell |
10,494
-11
| -0.1% | -$1.06K | 0.01% | 584 |
|
|
2023
Q3 | $1.07M | Hold |
10,505
| – | – | 0.01% | 590 |
|
|
2023
Q2 | $1.06M | Sell |
10,505
-516
| -5% | -$51.6K | 0.01% | 589 |
|
|
2023
Q1 | $1.01M | Hold |
11,021
| – | – | 0.01% | 577 |
|
|
2022
Q4 | $1,000K | Sell |
11,021
-167
| -1% | -$14.1K | 0.01% | 580 |
|
|
2022
Q3 | $850K | Hold |
11,188
| – | – | 0.01% | 579 |
|
|
2022
Q2 | $946K | Sell |
11,188
-125
| -1% | -$11K | 0.01% | 577 |
|
|
2022
Q1 | $993K | Sell |
11,313
-363
| -3% | -$31.4K | 0.01% | 597 |
|
|
2021
Q4 | $1.02M | Buy |
11,676
+38
| +0.3% | +$3.15K | 0.01% | 577 |
|
|
2021
Q3 | $952K | Sell |
11,638
-994
| -8% | -$89.4K | 0.01% | 587 |
|
|
2021
Q2 | $1.15M | Sell |
12,632
-126
| -1% | -$11.2K | 0.01% | 549 |
|
|
2021
Q1 | $1.09M | Sell |
12,758
-29
| -0.2% | -$2.6K | 0.01% | 553 |
|
|
2020
Q4 | $1.21M | Buy |
12,787
+339
| +3% | +$29.6K | 0.01% | 519 |
|
|
2020
Q3 | $1.08M | Buy |
12,448
+29
| +0.2% | +$2.51K | 0.01% | 512 |
|
|
2020
Q2 | $1.08M | Buy |
12,419
+344
| +3% | +$29.7K | 0.01% | 520 |
|
|
2020
Q1 | $996K | Buy |
12,075
+758
| +7% | +$67.6K | 0.01% | 503 |
|
|
2019
Q4 | $1.07M | Buy |
11,317
+51
| +0.5% | +$4.58K | 0.01% | 524 |
|
|
2019
Q3 | $979K | Hold |
11,266
| – | – | 0.01% | 531 |
|
|
2019
Q2 | $1.03M | Sell |
11,266
-470
| -4% | -$39.8K | 0.01% | 378 |
|
|
2019
Q1 | $1.01M | Sell |
11,736
-9
| -0.1% | -$723 | 0.01% | 373 |
|
|
2018
Q4 | $903K | Sell |
11,745
-166
| -1% | -$12.9K | 0.01% | 348 |
|
|
2018
Q3 | $920K | Buy |
11,911
+2,729
| +30% | +$202K | 0.01% | 364 |
|
|
2018
Q2 | $622K | Buy |
9,182
+103
| +1% | +$7.11K | 0.01% | 396 |
|
|
2018
Q1 | $658K | Hold |
9,079
| – | – | 0.01% | 395 |
|
|
2017
Q4 | $683K | Sell |
9,079
-334
| -4% | -$25.2K | 0.01% | 394 |
|
|
2017
Q3 | $724K | Buy |
9,413
+3,459
| +58% | +$261K | 0.01% | 383 |
|
|
2017
Q2 | $445K | Sell |
5,954
-231
| -4% | -$16.4K | ﹤0.01% | 414 |
|
|
2017
Q1 | $412K | Sell |
6,185
-1,650
| -21% | -$110K | ﹤0.01% | 437 |
|
|
2016
Q4 | $511K | Sell |
7,835
-1,395
| -15% | -$90.5K | 0.01% | 411 |
|
|
2016
Q3 | $653K | Sell |
9,230
-5,917
| -39% | -$431K | 0.01% | 379 |
|
|
2016
Q2 | $1.12M | Sell |
15,147
-114
| -0.7% | -$7.88K | 0.01% | 336 |
|
|
2016
Q1 | $991K | Buy |
15,261
+3,208
| +27% | +$218K | 0.01% | 338 |
|
|
2015
Q4 | $929K | Buy |
12,053
+1,044
| +9% | +$82.9K | 0.01% | 361 |
|
|
2015
Q3 | $907K | Hold |
11,009
| – | – | 0.01% | 337 |
|
|
2015
Q2 | $970K | Sell |
11,009
-1,959
| -15% | -$180K | 0.01% | 347 |
|
|
2015
Q1 | $1.15M | Buy |
12,968
+1,920
| +17% | +$170K | 0.02% | 316 |
|
|
2014
Q4 | $917K | Buy |
11,048
+1,116
| +11% | +$92.5K | 0.01% | 322 |
|
|
2014
Q3 | $838K | Hold |
9,932
| – | – | 0.01% | 328 |
|
|
2014
Q2 | $806K | Sell |
9,932
-101
| -1% | -$7.94K | 0.01% | 331 |
|
|
2014
Q1 | $764K | Sell |
10,033
-11
| -0.1% | -$802 | 0.01% | 321 |
|
|
2013
Q4 | $723K | Hold |
10,044
| – | – | 0.01% | 325 |
|
|
2013
Q3 | $690K | Buy |
10,044
+2,165
| +27% | +$143K | 0.01% | 322 |
|
|
2013
Q2 | $499K | Buy |
+7,879
| New | +$513K | 0.01% | 328 |
|
Other funds holding NVS
Silvercrest Asset Management's NVS Position: Q1 2026 in Review
Silvercrest Asset Management reduced its Novartis (NVS) stake by 6.9% in Q1 2026, selling an estimated $138K and leaving 12,125 shares worth $1.85M. The position accounts for 0.01% of the portfolio, ranked #536.
Silvercrest Asset Management first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Silvercrest Asset Management held 12,125 shares of Novartis worth $1.85M as of Q1 2026.
- Silvercrest Asset Management sold 900 Novartis shares in Q1 2026, an estimated $138K.
- Novartis made up 0.01% of Silvercrest Asset Management's portfolio in Q1 2026, its #536 holding.
- Silvercrest Asset Management first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.